Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
Cosmos Health (NASDAQ:COSM) has received a new order for 80,000 units of its Sky Premium Life products from Pharmalink for distribution in the United Arab Emirates (UAE). This follows the successful sell-out of their initial 130,000-unit order. The orders are part of an exclusive distribution agreement with Pharmalink, who handles all sales, marketing, regulatory affairs, logistics, and distribution activities in the UAE. The company aims to exceed 3 million units in cumulative orders over the first five years of the partnership. CEO Greg Siokas highlighted the growing momentum of Sky Premium Life nutraceuticals in the UAE market.
Cosmos Health (NASDAQ:COSM) ha ricevuto un nuovo ordine di 80.000 unità dei suoi prodotti Sky Premium Life da Pharmalink per la distribuzione negli Emirati Arabi Uniti (UAE). Questo arriva dopo il successo della vendita completa del loro ordine iniziale di 130.000 unità. Gli ordini fanno parte di un accordo esclusivo di distribuzione con Pharmalink, che gestisce tutte le attività di vendita, marketing, regolamentazione, logistica e distribuzione negli UAE. L'azienda punta a superare 3 milioni di unità in ordini cumulativi nei primi cinque anni della partnership. Il CEO Greg Siokas ha sottolineato il crescente slancio dei nutraceutici Sky Premium Life nel mercato degli UAE.
Cosmos Health (NASDAQ:COSM) ha recibido un nuevo pedido de 80,000 unidades de sus productos Sky Premium Life por parte de Pharmalink para su distribución en los Emiratos Árabes Unidos (EAU). Esto sigue al exitoso agotamiento de su pedido inicial de 130,000 unidades. Los pedidos forman parte de un acuerdo exclusivo de distribución con Pharmalink, que se encarga de todas las ventas, marketing, asuntos regulatorios, logística y distribución en los EAU. La compañía tiene como objetivo superar los 3 millones de unidades en pedidos acumulados durante los primeros cinco años de la asociación. El CEO Greg Siokas destacó el creciente impulso de los nutracéuticos Sky Premium Life en el mercado de los EAU.
Cosmos Health (NASDAQ:COSM)는 Pharmalink로부터 80,000개의 Sky Premium Life 제품 추가 주문을 받아 아랍에미리트(UAE)에 배포할 예정입니다. 이는 초기 130,000개 주문이 성공적으로 완판된 데 따른 것입니다. 이 주문들은 Pharmalink와의 독점 유통 계약의 일부로, Pharmalink는 UAE 내 모든 판매, 마케팅, 규제 업무, 물류 및 유통을 담당합니다. 회사는 파트너십 첫 5년 동안 누적 주문량 300만 개을 초과하는 것을 목표로 하고 있습니다. CEO Greg Siokas는 UAE 시장에서 Sky Premium Life 뉴트라슈티컬 제품의 성장세를 강조했습니다.
Cosmos Health (NASDAQ:COSM) a reçu une nouvelle commande de 80 000 unités de ses produits Sky Premium Life de la part de Pharmalink pour distribution aux Émirats arabes unis (EAU). Cela fait suite à la vente complète de leur commande initiale de 130 000 unités. Ces commandes s'inscrivent dans le cadre d'un accord de distribution exclusif avec Pharmalink, qui gère toutes les ventes, le marketing, les affaires réglementaires, la logistique et la distribution aux EAU. L'entreprise vise à dépasser 3 millions d'unités en commandes cumulées au cours des cinq premières années du partenariat. Le PDG Greg Siokas a souligné l'élan croissant des nutraceutiques Sky Premium Life sur le marché des EAU.
Cosmos Health (NASDAQ:COSM) hat eine neue Bestellung über 80.000 Einheiten seiner Sky Premium Life Produkte von Pharmalink für den Vertrieb in den Vereinigten Arabischen Emiraten (VAE) erhalten. Dies folgt auf den erfolgreichen Ausverkauf ihrer ersten Bestellung von 130.000 Einheiten. Die Bestellungen sind Teil einer exklusiven Vertriebsvereinbarung mit Pharmalink, das alle Verkaufs-, Marketing-, Regulierungs-, Logistik- und Vertriebsaktivitäten in den VAE übernimmt. Das Unternehmen strebt an, in den ersten fünf Jahren der Partnerschaft kumulierte Bestellungen von über 3 Millionen Einheiten zu erreichen. CEO Greg Siokas hob die zunehmende Dynamik der Sky Premium Life Nutraceuticals auf dem VAE-Markt hervor.
- Initial order of 130,000 units completely sold out, demonstrating strong market demand
- Secured additional 80,000-unit follow-up order, showing continued sales momentum
- Partnership with one of UAE's largest healthcare organizations provides strong distribution network
- On track towards 5-year goal of over 3 million units
- None.
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE).
This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Company’s objective of surpassing 3 million units in cumulative orders over the first five years. Pharmalink is responsible for all sales, marketing, regulatory affairs, logistics, and distribution activities related to Sky Premium Life products in the UAE.
Greg Siokas, CEO of Cosmos Health, stated: “We are thrilled to see our Sky Premium Life nutraceuticals gaining strong momentum in the UAE. This continued traction underscores the strength of our brand and the effectiveness of our partnership with Pharmalink, one of the largest healthcare organizations in the country, which positions us well to capture meaningful market share in this high-growth region.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
FAQ
What is the size of Cosmos Health's (COSM) new order from Pharmalink in UAE?
How many Sky Premium Life units did Pharmalink initially order from COSM?
What is Cosmos Health's (COSM) unit sales target in UAE over 5 years?
What is Pharmalink's role in COSM's UAE distribution agreement?
